CSRHub is the world’s largest CSR (corporate social responsibility) and sustainability ratings and information database.

Pfizer Inc. is a global research-based developer, manufacturer, and distributor of pharmaceuticals and related products. Pfizer’s diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and a range of consumer products. Among others, Pfizer's key pharmaceutical products include Lipitor, Zoloft, Viagra and Celebrex.

Ticker: PFE ISIN: US7170811035
Address: 235 East 42nd Street , USA , New York , NY , 10017 Website: Pfizer Inc.
Phone #: 1-212-7332323 CSR Web Area: SUBSCRIPTION INFO

Basic Corporate Social Responsibility (CSR) Ratings

  Overall Community Employees Environment Governance
Pfizer Inc. 60 56 61 65 54
Pharmaceutical & Medicine Manufacturing
SUBSCRIPTION INFO
All company average 55 55 56 58 52
USA
SUBSCRIPTION INFO

Percentile Rankings

Rankings are in percentile terms, compared to other companies in the same industry and country Overall Community Employees Environment Governance
Pfizer Inc. 75% 53% 66% 73% 53%
Pharmaceutical & Medicine Manufacturing
SUBSCRIPTION INFO
USA
SUBSCRIPTION INFO

Ratings History

Only subscribers can interact with the graph.

More CSR Rating Details

  Community Employees
Community Dev & Philanthropy Product Human Rights & Supply Chain Compensation & Benefits Diversity & Labor Rights Training, Health & Safety
Pfizer Inc.
SUBSCRIPTION INFO
Pharmaceutical & Medicine Manufacturing
SUBSCRIPTION INFO
All company average 53 54 55 58 55 55
USA
SUBSCRIPTION INFO

Environment Governance
Energy & Climate Change Environmant Policy & Reporting Resource Management Board Leadership Ethics Transparency & Reporting
Pfizer Inc.
SUBSCRIPTION INFO
Pharmaceutical & Medicine Manufacturing
SUBSCRIPTION INFO
All company average 57 58 57 50 55 51
USA
SUBSCRIPTION INFO

Percentile rankings

Rankings are in percentile terms, compared to other companies in the same industry and country Community Employees
Community Dev & Philantrophy Product Human Rights & Supply Chain Compensation & Benefits Diversity & Labor Rights Training, Health & Safety
Pfizer Inc. 81% 45% 29% 69% 47% 71%
Pharmaceutical & Medicine Manufacturing
SUBSCRIPTION INFO
USA
SUBSCRIPTION INFO

Environment Governance
Energy & Climate Change Environment Policy & Reporting Resource Management Board Leadership Ethics Transparency & Reporting
Pfizer Inc. 79% 77% 63% 58% 39% 72%
Pharmaceutical & Medicine Manufacturing
SUBSCRIPTION INFO
USA
SUBSCRIPTION INFO

5 Special Issues Affect This Company (see a list of issues here)

Working Mother-Friendly Military Contractor Gay & Lesbian Sensitive Diverse Board Animal Test User
# of Sources 10 1 1 3 6
# of co. % of co. # of co. % of co. # of co. % of co. # of co. % of co. # of co. % of co.
Pharmaceutical & Medicine Manufacturing
SUBSCRIPTION INFO
Overall database 46 0.5 756 8.1 266 2.8 111 1.2 115 1.2
USA
SUBSCRIPTION INFO

CSRHub Has 119 Data Sources (65 Are Currently Active) for This Company

= sources impacting the current ratings
= sources not impacting the current ratings, but included in earlier ratings for this company
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO

Original Data Values

(unsubscribed users can see the list, subscribers can see the data details for most sources)

Data source name

Data source element name Minimum value Value provided by datasource Maximum value Data description
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
Boston College Center for Corporate Citizenship (BCCCC)
SUBSCRIPTION INFO
SUBSCRIPTION INFO
Brand Value / Enterprise Value (%) -48.164682123 0.0686 316.6056 NA
Brand Value 2012 557.8732 NA
BSI 50 66.7163 88.4717 NA
Domicile UNITED STATES NA
Enterprise Value NA 17391.195 NA NA
Reviewed ? YES NA
Sector Consumer, Non-cyclical NA
SUBSCRIPTION INFO
Brand Value 2013 11.095 2911.8884 67875.2014 NA
BSI 50 71.5957 89.6275 NA
Domicile UNITED STATES NA
Sector Consumer, Non-cyclical NA
Reviewed LW NA
Brand Rating 2013 BBB AA AAA+ NA
Enterprise Value 2013 0 117908.362 435750.9811
SUBSCRIPTION INFO
Brand Value / Enterprise Value (%) 0.009 0.0217 1.07 NA
Brand Value 2014 10 3868.5171 87304 A brand strength is assessed by using our Brand Strength Index framework. This benchmarks the strength, risk and future potential of a brand relative to its competitors by assessing input measures, brand equity measures, and output performance across four
BSI 51.3 79.0504 94.2 NA
Domicile UNITED STATES NA
Enterprise Value 2014 66 191318.9129 526619 NA
Sector Consumer, Non-cyclical NA
BSR Member
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
Proxy filed Yes NA
Proxy voting decisions for the company http://www.calpers-governance.org/proxyvoting/proxy/ticker-results?ticker=PFE NA
SUBSCRIPTION INFO
Proxy voting decisions for the company http://www.calpers-governance.org/proxyvoting/proxy/ticker-results?ticker=PFE# NA
SUBSCRIPTION INFO
Percent of brands that use animal testing 100 1 0 NA
Number of brands that don't use animal testing 0 NA 11 NA
SUBSCRIPTION INFO
0. Further Information NA REFERENCES: Pfizer Fact Sheet: http://www.pfizer.com/about/leadership_and_structure/company_fact_sheet.jsp 2011 Annual Review: attached and at http://www.pfizer.com/investors/financial_reports/annual_reports/2011/index.jsp NA NA
0.1. Introduction - Please give a general description and introduction to your organization. NA Pfizer Inc: "Working Together for a Healthier World" Good health is vital to all of us, and finding sustainable solutions to the most pressing health care challenges of our world cannot wait. That's why we at Pfizer are committed to applying science and o NA NA
5.1e Identified climate change risks driven by changes in other climate-related developments? NA No NA NA
5.1f. Please describe (i) the potential financial implications of the risk before taking action; (ii) the methods you are using to manage this risk; (iii) the costs associated with these actions NA NA NA NA
5.1g. Please explain why you do not consider your company to be exposed to risks driven by changes in regulation that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA NA
5.1h. Please explain why you do not consider your company to be exposed to risks driven by physical climate parameters that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA NA
5.1i. Please explain why you do not consider your company to be exposed to risks driven by changes in other climate-related developments that have the potential to generate a substantive change in your business operations, revenue or expenditure NA Pfizer has performed a detailed assessment of regulatory risk and physical risk and captured those potential outcomes in the previous responses. Through our operating risk review process, we have identified the need to perform a formal climate change risk NA NA
6. Attachments NA https://www.cdproject.net/Sites/2012/83/14683/Investor CDP 2012/Shared Documents/Attachments/InvestorCDP2012/6.ClimateChangeOpportunities/Pfizer 2011 Annual Review - NTD.pdf NA NA
6. Further Information NA REFERENCES: Q6.1d Relevant sections from Pfizer's 2011 Annual Review are attached. Video: http://www.pfizer.com/news/featured_stories/featured_stories_tropical_diseases.jsp Website: http://www.pfizer.com/responsibility/global_health/global_health.jsp NA NA
6.1. Have you identified any climate change opportunities (current or future) that have the potential to generate a substantive change in your business operations, revenue or expenditure? Tick all that apply NA Opportunities driven by changes in regulation; Opportunities driven by changes in physical climate parameters; Opportunities driven by changes in other climate-related developments NA NA
6.1a Identified climate change opportunities that are driven by changes in regulation? NA Yes NA NA
6.1b. Please describe (i) the potential financial implications of the opportunity; (ii) the methods you are using to manage this opportunity; (iii) the costs associated with these actions NA Changes in the regulatory landscape could present potential opportunities for Pfizer and include ongoing issues currently as well as those projected out 6-10 years; however, we do not see these opportunities generating a substantive change in business ope NA NA
6.1c Identified climate change opportunities that are driven by changes in physical climate parameters? NA Yes NA NA
14. Attachments NA https://www.cdproject.net/Sites/2012/83/14683/Investor CDP 2012/Shared Documents/Attachments/InvestorCDP2012/14.EmissionsTrading/Pfizer EU ETS Allocation Summary 2011.xlsx NA NA
6.1d. Please describe (i) the potential financial implications of the opportunity; (ii) the methods you are using to manage this opportunity; (iii) the costs associated with these actions NA Changes in the physical landscape could present potential opportunities for Pfizer which are projected out 6-10 years; however, we do not see this opportunity generating a substantive change in business operations, revenue or expenditure. As a pharmaceu NA NA
6.1e Identified opportunities that are driven by changes in other climate-related developments? NA Yes NA NA
6.1f. Please describe (i) the potential financial implications of the opportunity; (ii) the methods you are using to manage this opportunity; (iii) the costs associated with these actions NA Changes in the other areas could present potential opportunities for Pfizer and include trending issues 1-5 years; however, we do not see these opportunities generating a substantive change in business operations, revenue or expenditure. During the past NA NA
13. Attachments NA NA NA NA
11. Attachments NA NA NA NA
11. Further Information NA NA NA NA
11.1. Do you consider that the grid average factors used to report Scope 2 emissions in Question 8.3 reflect the contractual arrangements you have with electricity suppliers? NA Yes NA NA
11.1a. You may report a total contractual Scope 2 figure in response to this question. Please provide your total global contractual Scope 2 GHG emissions figure in metric tonnes CO2e 0 NA 17902000 NA
11.2. Has your organization retired any certificates, e.g. Renewable Energy Certificates, associated with zero or low carbon electricity within the reporting year or has this been done on your behalf? NA Yes NA NA
3.1e. Please explain (i) why not; and (ii) forecast how your emissions will change over the next five years NA NA NA NA
3.2. Does the use of your goods and/or services directly enable GHG emissions to be avoided by a third party? No Yes Yes NA
3.2a. Please provide details (see guidance) NA Although the environmental impact (greenhouse gas emissions) associated with the production of pork in the United States is relatively low (0.33% of the total U.S. GHG emissions)[1], incremental reductions in these emissions remain a high priority. As p NA NA
3.3c Number of methods used to drive investment in emissions reduction activities. 0 5 12 NA
3.3c. What methods do you use to drive investment in emissions reduction activities? NA Compliance with regulatory requirements/standards, Internal finance mechanisms, Internal incentives/recognition programs, Employee engagement, Other NA NA
5. Attachments NA NA NA NA
5. Further Information NA NA NA NA
5.1. Have you identified any climate change risks (current or future) that have potential to generate a substantive change in your business operations, revenue or expenditure? Tick all that apply NA Risks driven by changes in regulation; Risks driven by changes in physical climate parameters NA NA
5.1a Identified risks driven by changes in regulation? NA Yes NA NA
5.1b. Please describe (i) the potential financial implications of the risk before taking action; (ii) the methods you are using to manage this risk; and (iii) the costs associated with these actions NA Changes in the regulatory landscape present several potential risks for Pfizer and include ongoing issues as well as those projected 1-5 years; however, we do not see any of these risks generating a substantive change in business operations, revenue or ex NA NA
14. Further Information NA REFERENCE: Table summarzing the EU ETS allocations attached. NA NA
1.1. Where is the highest level of direct responsibility for climate change within your company? No individual or committee with overall responsibility for climate change Senior Manager/Officer Individual/Sub-set of the Board or other committee appointed by the Board NA
1.1a. Please identify the position of the individual or name of the committee with this responsibility NA NOTE: Pfizer re-calibrated its responses to this section (compared from last year) to address the questions more specifically. "Senior Manager" refers to executive or senior leadership at the EVP / SVP level who has direct responsibility for climate chang NA NA
1.2. Do you provide incentives for the management of climate change issues, including the attainment of targets? No Yes Yes NA
13. Further Information NA NA NA NA
13.1. How do your absolute emissions (Scope 1 and 2 combined) for the reporting year compare to the previous year? Increased Decreased Decreased NA
13.1a (i) If absolute emissions (Scope 1 and 2 combined) have increased, decreased or remained the same overall compared to the previous year, state direction of change NA Slightly Decreased NA NA
13.1a (ii) If absolute emissions (Scope 1 and 2 combined) have increased, decreased or remained the same overall compared to the previous year, state the reason for the direction of change NA Decrease: Emissions reduction activities, Increase: Divestment, Decrease: Acquisitions, Decrease: Change in boundary, NA NA
13.1a (iii) If emissions have increased, decreased or remained the same overall, provide the emissions value (%) NA Decrease: 24, Increase: , Emission value for which direction is not stated: NA NA
2012 Score 0 87 100 NA
2012 Performance Band E A A NA
2.3a. Please explain (i) the engagement process and (ii) actions you are advocating NA Position: In 2011, Pfizer experienced increased scrutiny from various stakeholders (including Socially Responsible Investors) with respect to climate change, our public position and the apparent misalignment between our views and those of certain trade as NA NA
8.8. Are carbon dioxide emissions from the combustion of biologically sequestered carbon (i.e. carbon dioxide emissions from burning biomass/biofuels) relevant to your company? No Yes Yes NA
8.8a. Please provide the emissions in metric tonnes CO2e 0.01 153 27263000 NA
Management 4. Attachments NA https://www.cdproject.net/Sites/2012/83/14683/Investor CDP 2012/Shared Documents/Attachments/InvestorCDP2012/4.Communication/Pfizer_EHS_Platform.pdf NA NA
Management 4. Have you published information about your company’s response to climate change and GHG emissions performance for this reporting year in other places than in your CDP response? NA 6 NA NA
5.1d. Please describe (i) the potential financial implications of the risk before taking action; (ii) the methods you are using to manage this risk; and (iii) the costs associated with these actions NA Changes in the physical landscape present several potential risks for Pfizer and include those projected 1-5 years; however, we do not see any of these risks generating a substantive change in business operations, revenue or expenditure. Pfizer perceives NA NA
2. Attachments NA https://www.cdproject.net/Sites/2012/83/14683/Investor CDP 2012/Shared Documents/Attachments/InvestorCDP2012/2.Strategy/Pfizer_Climate_Change_Position_Statement.pdf NA NA
2. Further Information NA COMMENT Q2.3a: Additional transparency through disclosure can sometimes increase scrutiny whereby companies are solicited to take immediate action, as was the case earlier this year (2012) with the Heartland Institute. Pfizer does not agree with the Heart NA NA
5.1c Identified climate change risks driven by change in physical climate parameters? NA Yes NA NA
2.1. Please select the option that best describes your risk management procedures with regard to climate change risks and opportunities NA A specific climate change risk management process NA NA
2.1a. Please provide further details (see guidance) NA Position: As a science-based health care company, Pfizer recognizes the risks posed by global climate change, such as more severe weather events and potential adverse impacts on human health, and has, as a precautionary step, taken significant voluntary a NA NA
2.2. Is climate change integrated into your business strategy? No Yes Yes NA
2.2a. Please describe the process and outcomes (see guidance) NA Business Strategy: In 2011 and with changes in executive leadership and Pfizer's business model, the strategic priorities were recalibrated and simplified into a set of four core imperatives. In the 2012 Proxy Statement and 2011 Annual Review, CEO letter NA NA
2.2b. Please explain why not NA NA NA NA
2.3. Do you engage with policy makers to encourage further action on mitigation and/or adaptation? No Yes Yes NA
3. Attachments NA https://www.cdproject.net/Sites/2012/83/14683/Investor CDP 2012/Shared Documents/Attachments/InvestorCDP2012/3.TargetsandInitiatives/Pfizer EPD261 - Improvac.pdf NA NA
3. Further Information NA REFERENCES (includes footnotes in 3.2a) EPD 261 attached. NA NA
3.1. Did you have an emissions reduction target that was active (ongoing or reached completion) in the reporting year? No Absolute target Absolute and intensity targets NA
14.1. Do you participate in any emission trading schemes? No, and we do not currently anticipate doing so in the next two years Yes Yes NA
14.2. Has your company originated any project-based carbon credits or purchased any within the reporting period? No Yes Yes NA
6.1g. Please explain why you do not consider your company to be exposed to opportunities driven by changes in regulation that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA NA
6.1h. Please explain why you do not consider your company to be exposed to opportunities driven by physical climate parameters that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA NA
6.1i. Please explain why you do not consider your company to be exposed to opportunities driven by changes in other climate-related developments that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA NA
7. Attachments NA https://www.cdproject.net/Sites/2012/83/14683/Investor CDP 2012/Shared Documents/Attachments/InvestorCDP2012/7.EmissionsMethodology/Pfizer 2012 CDP submittal Q7.4 Emission Factors.xls NA NA
7. Further Information NA REFERENCES Q7.2: GHG Protocol (revised edition) - too large to uploadhttp://www.wri.org/publication/greenhouse-gas-protocol-corporate-accounting-and-reporting-standard-revised-edition Q7.3: IPCC (SAR Assessment 100) - too large to uploadhttp://ipcc.ch/p NA NA
7.1. Please provide your base year and base year emissions (Scopes 1 and 2) NA NA NA NA
0.4. Currency selection Please select the currency in which you would like to submit your response. All financial information contained in the response should be in this currency. NA USD($) NA NA
1. Attachments NA https://www.cdproject.net/Sites/2012/83/14683/Investor CDP 2012/Shared Documents/Attachments/InvestorCDP2012/1.Governance/Pfizer Board Charter Corp Gov.pdf NA NA
1. Further Information NA REFERENCES: All Board Charters may be found at the link below, three of which are referenced in Q1.1a are attached. http://www.pfizer.com/about/corporate_governance/board_committees_charters.jsp NA NA
8.7. Please indicate the verification/assurance status that applies to your Scope 2 emissions More than 0% but less than or equal to 20% NA More than 90% but less than or equal to 100% NA
11.1b. Explain the basis of the alternative figure (see guidance) NA NA
14.1b. What is your strategy for complying with the schemes in which you participate or anticipate participating? Pfizer has seven sites operating under the EU ETS. Each site is responsible for operating within their specific allowances and working through their respective energy management plans to identify and implement energy efficiency projects to reduce GHG emis NA
8.1. Please select the boundary you are using for your Scope 1 and 2 greenhouse gas inventory NA NA NA NA
8.2a. Please provide your gross global Scope 1 emissions figure in metric tonnes CO2e 92 NA 231902967 NA
8.3a. Please provide your gross global Scope 2 emissions figure in metric tonnes CO2e 293 NA 8071070 NA
8.4. Are there are any sources (e.g. facilities, specific GHGs, activities, geographies, etc.) of Scope 1 and Scope 2 emissions which are not included in your disclosure? NA Yes NA NA
8.6. Please indicate the verification/assurance status that applies to your Scope 1 emissions More than 0% but less than or equal to 20% NA More than 90% but less than or equal to 100% NA
SUBSCRIPTION INFO
8.7. Please indicate the verification/assurance status that applies to your Scope 2 emissions Third party verification or assurance underway but not yet complete - last years statement available Proportion of Scope 2 emissions that are verified/assured for 2011-2012/01 Jan 2012 - 31 Dec 2012 reporting period
8.7a. Please indicate the proportion of your Scope 2 emissions that are verified/assured More than 0% but less than or equal to 20% More than 90% but less than or equal to 100% More than 90% but less than or equal to 100%
8.7b Reporting Period From/To/Please provide further details of the verification/assurance undertaken, and attach the relevant statements/Type of verification or assurance/Relevant standard/Attach the document No Response
8.8. Are carbon dioxide emissions from biologically sequestered carbon relevant to your organization? Yes
8.8a. Please provide the emissions in metric tonnes CO2 433
8.8a. Please provide the emissions in metric tonnes CO2e 0.05 433 13638000
9.1. Do you have Scope 1 emissions sources in more than one country? Yes
9.1a Reporting Period From/To/Please complete the table below: Country/Region/Scope 1 metric tonnes CO2e 1 Jan 2012/31 Dec 2012/United States of America/658248
9.2. Please indicate which other Scope 1 emissions breakdowns you are able to provide (tick all that apply) NA By business division NA
9.2a Reporting Period From/To/Please break down your total gross global Scope 1 emissions by business division: Business division/Scope 1 emissions (metric tonnes CO2e) 1 Jan 2012/31 Dec 2012/Animal Health/115638
9.2b Reporting Period From/To/Please break down your total gross global Scope 1 emissions by facility: Facility/Scope 1 emissions (metric tonnes CO2e) No Response
9.2c Reporting Period From/To/Please break down your total gross global Scope 1 emissions by GHG type: GHG type/Scope 1 emissions (metric tonnes CO2e) No Response
9.2d Reporting Period From/To/Please break down your total gross global Scope 1 emissions by activity: Activity/Scope 1 emissions (metric tonnes CO2e) No Response
9.2e Reporting Period From/To/Please break down your total gross global Scope 1 emissions by legal structure: Legal structure/Scope 1 emissions (metric tonnes CO2e) No Response
0.3. Country list configuration Canada
0.4. Currency selection Please select the currency in which you would like to submit your response. All financial information contained in the response should be in this currency. USD($)
0.4. Please select the currency in which you would like to submit your response. USD($)
0.5. Please select if you wish to complete a shorter information request. NA
0.6. Modules NA As part of the Investor CDP information request, electric utilities, companies with electric utility activities or assets, companies in the automobile or auto component manufacture sectors and companies in the oil and gas industry should complete suppleme
1. Attachments NA NA NA
1. Further Information NA REFERENCES: Pfizer's EHS Policy may be found here: http://www.pfizer.com/files/responsibility/protecting_environment/Pfizer_EHS_Policy_Statement.pdf NA
1.1. Where is the highest level of direct responsibility for climate change within your company? No individual or committee with overall responsibility for climate change Individual/Sub-set of the Board or other committee appointed by the Board Individual/Sub-set of the Board or other committee appointed by the Board
1.1a. Please identify the position of the individual or name of the committee with this responsibility NA A member of Pfizer's Executive Leadership Team (ELT), the highest non-board governing body, sponsors the Environmental Sustainability Council and periodically reviews key issues requiring executive authority (e.g. policy issues, capital appropriations for NA
1.2. Do you provide incentives for the management of climate change issues, including the attainment of targets? No Yes Yes
1.2a. Who is entitled to benefit from these incentives? Executive officer/Monetary reward/Energy savings is a component of overall savings target included in goals against which CFO monetary awards were determined.
10.1. Do you have Scope 2 emissions sources in more than one country? Yes
10.1a Reporting Period: From/To/Please complete the table below: Country/Region/Scope 2 metric tonnes CO2e/Purchased and consumed electricity, heat, steam or cooling (MWh)/Purchased and consumed low carbon electricity, heat, steam or cooling (MWh) 1 Jan 2012/31 Dec 2012/United States of America/695568/1130042/
10.2. Please indicate which other Scope 2 emissions breakdowns you are able to provide (tick all that apply) NA By business division NA
10.2a Reporting Period From/To/Please break down your total gross global Scope 2 emissions by business division: Business division/Scope 2 emissions (metric tonnes CO2e) 1 Jan 2012/31 Dec 2012/Animal Health/221954
10.2b Reporting Period From/To/Please break down your total gross global Scope 2 emissions by facility: Facility/Scope 2 emissions (metric tonnes CO2e) No Response
10.2c Reporting Period: From/To/Please break down your total gross global Scope 2 emissions by activity: Activity/Scope 2 emissions (metric tonnes CO2e) No Response
10.2d Reporting Period: From/To/Please break down your total gross global Scope 2 emissions by legal structure: Legal structure/Scope 2 emissions (metric tonnes CO2e) No Response
11. Attachments NA NA NA
11. Further Information NA NA NA
11.1. What percentage of your total operational spend in the reporting year was on energy? More than 0% but less than or equal to 5% More than 0% but less than or equal to 5% More than 95% but less than or equal to 100%
11.2. Please state how much fuel, electricity, heat, steam, and cooling in MWh your organization has purchased and consumed during the reporting year: Energy type/MWh Fuel/5427010;Electricity/2087321;Heat/0;Steam/179130;Cooling/0
11.3. Please complete the table by breaking down the total "Fuel" figure entered above by fuel type: Fuels/MWh Other: Bagasse/11320
11.4. Please provide details of the electricity, heat, steam or cooling amounts that were accounted at a low carbon emission factor: Basis for applying a low carbon emission factor/MWh associated with low carbon electricity, heat, steam or cooling Non-grid connected low carbon heat, steam or cooling, generation owned by company/59754
12. Attachments NA
12. Further Information NA
12.1. How do your absolute emissions (Scope 1 and 2 combined) for the reporting year compare to the previous year? Decreased
12.1a Reason of change Emissions reduction activities, Divestment, Acquisitions, Mergers, Change in output, Change in methodology, Change in boundary, Change in physical operating conditions, Unidentified, Other
12.1a. Reason: Emissions value (percentage) Emissions reduction activities: 3.2/Divestment: 6.9/Acquisitions: 0.3/Change in boundary: 0.4/Other: 1.3
12.2. Please describe your gross combined Scope 1 and 2 emissions for the reporting year in metric tonnes CO2e per revenue: Intensity figure/Metric numerator/% change from previous year/Direction of change from previous year/Reason for change 4.024E-05/metric tonnes CO2e/1.99/Increase/Change in intensity due to reduction in revenue resulting primarily from the loss of exclusivity for key revenue-generating drugs
12.3. Please describe your gross combined Scope 1 and 2 emissions for the reporting year in metric tonnes CO2e per FTE: Intensity figure/Metric numerator/% change from previous year/Direction of change from previous year/Reason for change 25.94/metric tonnes CO2e/1.2/Increase/Change in intensity primarily due to headcount reduction
12.4. Please provide an additional intensity (normalized) metric that is appropriate to your business operations: Intensity figure/Metric numerator/% change from previous year/Direction of change from previous year/Reason for change 0.048/metric tonnes CO2e/9.5/Increase/Change in intensity primarily due to real estate consolidation (reduction of SQFT worldwide).
13.1. Do you participate in any emissions trading schemes? Yes
13.1b. What is your strategy for complying with the schemes in which you participate or anticipate participating? The strategy is to allow the scheme to incentivize sites to respond to carbon price signals by implementing emission reduction projects. As such the sites profit from sales of credits generated through sale or banking for future use.
13.2. Has your company originated any project-based carbon credits or purchased any within the reporting period? Yes
14. Attachments NA NA NA
14. Further Information NA REFERENCE: Table summarizing the EU ETS allocations attached. NA
14.1. Do you participate in any emission trading schemes? No, and we do not currently anticipate doing so in the next two years Yes Yes
14.1b. What is your strategy for complying with the schemes in which you participate or anticipate participating? The strategy is to allow the scheme to incentivize sites to respond to carbon price signals by implementing emission reduction projects. As such the sites profit from sales of credits generated through sale or banking for future use.
14.2. Has your company originated any project-based carbon credits or purchased any within the reporting period? No Yes Yes
14.2. Please indicate the verification/assurance status that applies to your Scope 3 emissions No third party verification or assurance
14.2a. Please indicate the proportion of your Scope 3 emissions that are verified/assured NA
14.3. Are you able to compare your Scope 3 emissions for the reporting year with those for the previous year for any sources? Yes
14.4. Do you engage with any of the elements of your value chain on GHG emissions and climate change strategies? (Tick all that apply) Yes, our suppliers
14.4a. Please give details of methods of engagement, your strategy for prioritizing engagements and measures of success Pfizer joined the CDP Supply Chain program in February 2013 in order to collect information and data about carbon emissions and water consumption from its most strategically important 1st tier suppliers of active pharmaceutical ingredients, consumer and p
14.4d. Please explain why not and any plans you have to develop an engagement strategy in the future NA
2. Attachments NA https://www.cdproject.net/sites/2013/83/14683/Investor CDP 2013/Shared Documents/Attachments/InvestorCDP2013/2.Strategy/Pfizer Climate Change Position Statement (2011).pdf NA
2. Further Information NA Pfizer is a member of several industry and trade groups that represent both the pharmaceutical industry and the business community at large in an effort to bring about consensus on broad policy issues that can impact Pfizer's business objectives and abili NA
2.1. Please select the option that best describes your risk management procedures with regard to climate change risks and opportunities NA Integrated into multi-disciplinary company wide risk management processes NA
2.1a. Please provide further details Position: As a science-based health care company, Pfizer recognizes the risks posed by global climate change, such as more severe weather events and potential adverse impacts on human health, and has, as a precautionary step, taken significant voluntary a
2.1a. Please provide further details (see guidance) NA Position: As a science-based health care company, Pfizer recognizes the risks posed by global climate change, such as more severe weather events and potential adverse impacts on human health, and has, as a precautionary step, taken significant voluntary a NA
2.2. Is climate change integrated into your business strategy? No Yes Yes
2.2a. Please describe the process and outcomes Position: Pfizer’s purpose is to innovate to bring therapies to patients that significantly improve their lives. Under the Environmental Sustainability Program, Pfizer’s climate change initiatives align with our company imperatives to: Innovate and Lead:
2.2a. Please describe the process and outcomes (see guidance) NA Position: Pfizer’s purpose is to innovate to bring therapies to patients that significantly improve their lives. Under the Environmental Sustainability Program, Pfizer’s climate change initiatives align with our company imperatives to: Innovate and Lead: NA
2.2b. Please explain why not NA NA NA
2.3. Do you engage in activities that could either directly or indirectly influence policy on climate change through any of the following? (tick all that apply) NA
2.3. Do you engage with policy makers to encourage further action on mitigation and/or adaptation? No No Response Yes
2.3a. On what issues have you been engaging directly?: Focus of legislation/Corporate Position/Details of engagement/Proposed solution NA
2.3a. Please explain (i) the engagement process and (ii) actions you are advocating NA NA NA
2.3b. Are you on the Board of any trade associations or provide funding beyond membership? NA
2.3c. Please enter the details of those trade associations that are likely to take a position on climate change legislation/Trade association NA
2.3d. Do you publically disclose a list of all the research organizations that you fund? NA
2.3e. Do you fund any research organizations to produce public work on climate change? NA
2.3f. Please describe the work and how it aligns with your own strategy on climate change NA
2.3g. Please provide details of the other engagement activities that you undertake NA
2.3h. What processes do you have in place to ensure that all of your direct and indirect activities that influence policy are consistent with your overall climate change strategy? NA
2.3i. Please explain why you do not engage with policy makers NA
3. Attachments NA https://www.cdproject.net/sites/2013/83/14683/Investor CDP 2013/Shared Documents/Attachments/InvestorCDP2013/3.TargetsandInitiatives/Pfizer EPD - Improvac.pdf NA
3. Further Information NA REFERENCES: 3.2a Footnote [2] - EPD 261 attached NA
3.1. Did you have an emissions reduction target that was active (ongoing or reached completion) in the reporting year? No Absolute target Absolute and intensity targets
3.1a. Absolute target/ID/Scope/% of emissions in scope/% reduction from base year/Base year/Base year emissions (metric tonnes CO2e)/Target year/Comment 1/Scope 1+2/100/20/2007/3295782/2012/Scope 1& 2 Emissions that includes: internal operations (manufacturing, commercial sites, R&D), fleet and aviation. Note that in 2007, 4,067 mt of emissions were added back into our footprint to account for th
3.1b. Intensity target/ID/Scope/% of emissions in scope/% reduction from base year/Metric/Base year/Normalized base year emissions/Target year/Comment No Response
3.1c. What change in absolute emissions this intensity target reflects/ID/Direction of change anticipated in absolute Scope 1+2 emissions at target completion?/% change anticipated in absolute Scope 1+2 emissions No Response
3.1d. Please provide details on your progress against this target made in the reporting year/ID/% complete (time)/% complete (emissions)/Comment 1/100/100/Pfizer is proud to report that we achieved a 5.5% reduction in GHG emissions in 2012 compared to 2011, contributing to an absolute reduction in GHG emissions of 27% from 2007 to 2012. Since 2000, Pfizer has set two aggressive GHG reduction goal
3.1e. Please explain (i) why not; and (ii) forecast how your emissions will change over the next five years NA NA NA
3.2. Does the use of your goods and/or services directly enable GHG emissions to be avoided by a third party? No Yes Yes
3.2a. Please provide details (see guidance) NA As part of the overall commitment to help farmers further reduce greenhouse gases, Pfizer Animal Health[1] sponsored and had validated a Life Cycle Assessment (LCA) for the Improvac® (also sold as Innosure, Improvest, Vivax)[2]. Improvac is a veterinary NA
3.3. Did you have emissions reduction initiatives that were active within the reporting year (this can include those in the planning and/or implementation phases) No Yes Yes
3.3a. Please identify the total number of projects at each stage of development, and for those in theimplementation stages, the estimated CO2e savings/Stage of development/3.3a. Number of projects/Total estimated annual CO2e savings in metric tonnes CO2e Under investigation/64/
3.3c Number of methods used to drive investment in emissions reduction activities. 0 5 13 Number of methods used to drive investment in emissions reduction activities.
3.3c. What methods do you use to drive investment in emissions reduction activities? NA Compliance with regulatory requirements/standards, Internal finance mechanisms, Internal incentives/recognition programs, Employee engagement, Other NA
3.3c. What methods do you use to drive investment in emissions reduction activities?/Comment Compliance with regulatory requirements/standards/A priority is given to fund projects associated with regulatory compliance requirements.
4. Attachments NA
4. Have you published information about your company’s response to climate change and GHG emissions performance for this reporting year in other places than in your CDP response? - Further Information REFERENCES: Attachments supporting each communications are included within the exception of:• Energy and climate change content on www.pfizer.com/ehs
4.1. Have you published information about your company’s response to climate change and GHG emissions performance for this reporting year in other places than in your CDP response? 5 The number of corporate annual reports and voluntary publications (complete and/or underway) made about the company’s response to climate change and GHG emissions performance
5. Attachments NA NA NA
5. Further Information NA NA NA
5.1. Have you identified any climate change risks (current or future) that have potential to generate a substantive change in your business operations, revenue or expenditure? Tick all that apply NA Risks driven by changes in physical climate parameters; Risks driven by changes in other climate-related developments NA
5.1a. Please describe your risks driven by changes in regulation /ID/Risk driver/ Description/Potential impact/Timeframe/Direct/Indirect/Likelihood/Magnitude of impact No Response
5.1b. Please describe (i) the potential financial implications of the risk before taking action; (ii) the methods you are using to manage this risk and (iii) the costs associated with these actions NA
5.1c. Climate change risks driven by change in physical climate parameters Yes
5.1c. Please describe your risks that are driven by change in physical climate parameters/ID/Risk driver/Description/Potential impact/Timeframe/Direct/Indirect/Likelihood/Magnitude of impact PR1/Tropical cyclones (hurricanes and typhoons)/Risk that severe weather takes significant Pfizer Manufacturing or Logistics assets off-line for extended period (e.g., CAT 4/5 hurricane impacts Pfizer PR sites). Potential harm: damage to property, product
5.1d. Please describe (i) the potential financial implications of the risk before taking action; (ii) the methods you are using to manage this risk; and (iii) the costs associated with these actions NA General commentsChanges in the physical environment associated with climate change are considered capable of substantive impact to Pfizer’s business over the next 1-5 years, albeit with a very low likelihood.[1] Pfizer perceives financial risk associate NA
5.1e. Please describe your risks that are driven by changes in other climate-related developments/ID/Risk driver/Description/Potential impact/Timeframe/Direct/Indirect/Likelihood/Magnitude of impact 12008/Change in temperature extremes/Increased frequency of high and low temperatures/Increased operational cost/6-10 years/Indirect (Supply chain)/Virtually certain/Low-medium
5.1e.Climate change risks driven by changes in other climate-related developments Yes
5.1f. Please describe (i) the potential financial implications of the risk before taking action; (ii) the methods you are using to manage this risk; (iii) the costs associated with these actions NA OR1 (i) Potential financial implications As indicated in Section 6.1e and f, Pfizer sees the Changing Consumer Behaviour as an emerging opportunity in which customers are increasing requesting information on our sustainability and climate change accomplis NA
5.1g. Please explain why you do not consider your company to be exposed to risks driven by changes in regulation that have the potential to generate a substantive change in your business operations, revenue or expenditure NA i) Pfizer has considered the Regulatory Risks associated with climate change listed below, and concluded that none of them present a risk of substantive impact to its business over the next 1-5 years: Carbon taxes Cap and Trade schemes Fuel/energy taxes NA
5.1h. Please explain why you do not consider your company to be exposed to risks driven by physical climate parameters that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA
5.1i. Please explain why you do not consider your company to be exposed to risks driven by changes in other climate-related developments that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA
6. Attachments NA NA NA
6. Further Information NA NA NA
6.1. Have you identified any climate change opportunities (current or future) that have the potential to generate a substantive change in your business operations, revenue or expenditure? Tick all that apply NA Opportunities driven by changes in physical climate parameters; Opportunities driven by changes in other climate-related developments NA
6.1. Have you identified any climate change opportunities (current or future) that have the potential to generate a substantive change in your business operations, revenue or expenditure? -Transparency Yes
6.1a. Please describe your opportunities that are driven by changes in regulation/ID/Opportunity driver/Description/Potential impact/Timeframe/Direct/Indirect/Likelihood/Magnitude of impact No Response
6.1b. Please describe (i) the potential financial implications of the opportunity; (ii) the methods you are using to manage this opportunity and (iii) the costs associated with these actions NA
6.1c. Please describe the opportunities that are driven by changes in physical climate parameters Yes
6.1d. Please describe (i) the potential financial implications of the opportunity; (ii) the methods you are using to manage this opportunity and (iii) the costs associated with these actions Position: Pfizer’s efforts to advance the treatment of neglected tropical diseases (NTDs) contribute to mitigating the secondary effects of a changing climate. As a pharmaceutical company, Pfizer does not generally develop or manufacture products that hav
6.1e. Please describe the opportunities that are driven by changes in other climate-related developments Yes
6.1f. Please describe (i) the potential financial implications of the opportunity; (ii) the methods you are using to manage this opportunity; (iii) the costs associated with these actions NA OO1 (i) Potential financial implications Pfizer perceives “Changing Consumer Behaviour” as an emerging area of financial opportunity. Increasingly, global tender requests and supplier surveys request information on our environmental sustainability program NA
6.1g. Please explain why you do not consider your company to be exposed to opportunities driven by changes in regulation that have the potential to generate a substantive change in your business operations, revenue or expenditure NA i) Changes in the regulatory landscape could present potential opportunities for Pfizer and include ongoing issues currently as well as those projected out 6-10 years; however, we do not see these opportunities generating a substantive change in business NA
6.1h. Please explain why you do not consider your company to be exposed to opportunities driven by physical climate parameters that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA
6.1i. Please explain why you do not consider your company to be exposed to opportunities driven by changes in other climate-related developments that have the potential to generate a substantive change in your business operations, revenue or expenditure NA NA NA
7. Attachments NA https://www.cdproject.net/sites/2013/83/14683/Investor CDP 2013/Shared Documents/Attachments/InvestorCDP2013/7.EmissionsMethodology/2012 CDP Carbon Pfizer Q7.4.xls NA
7. Further Information NA Q7.2: GHG Protocol (revised edition) - too large to uploadhttp://www.wri.org/publication/greenhouse-gas-protocol-corporate-accounting-and-reporting-standard-revised-edition Q7.3: IPCC (SAR Assessment 100) - too large to uploadhttp://ipcc.ch/pdf/climate- NA
7.1. Please provide your base year and base year emissions (Scopes 1 and 2)/7.1. Base year From Date:/To Date:/ Scope 1 Base year emissions (metric tonnes CO2e)/N39Scope 2 Base year emissions (metric tonnes CO2e) 2007-01-01/2007-12-31/1641442/1650273
7.2. Please give the name of the standard, protocol or methodology you have used to collect activity data and calculate Scope 1 and Scope 2 emissions NA The Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard (Revised Edition) NA
7.3. Please give the source for the global warming potentials you have used Gas/Reference CO2/IPCC Second Assessment Report (SAR - 100 year)
7.4. Please give the emissions factors you have applied and their origin; alternatively, please attach an Excel spreadsheet with this data Fuel/Material/Energy/Emission Factor/Unit/Reference Other: See Attached Worksheet///Comprehensive emission factor Information may be found in the attached template as provided by CDP
8.1. Please select the boundary you are using for your Scope 1 and 2 greenhouse gas inventory NA Operational control NA Boundary used for Scope 1 and 2 greenhouse gas inventory during 2011-2012/01 Jan 2012 - 31 Dec 2012 reporting period
8.2. Please provide your gross global Scope 1 emissions figure in metric tonnes CO2e NA Gross global Scope 1 emissions figure in metric tonnes CO2e for 2011 - 2012/01 Jan 2012 - 31 Dec 2012 reporting period
8.2. Please provide your gross global Scope 1 emissions figures in metric tonnes CO2e 1217736
8.3. Please provide your gross global Scope 2 emissions figures in metric tonnes CO2e NA
8.4. Are there are any sources (e.g. facilities, specific GHGs, activities, geographies, etc.) of Scope 1 and Scope 2 emissions which are not included in your disclosure? NA Yes NA Proportion of Scope 1 emissions that are verified/assured for 2011 - 2012/01 Jan 2012 - 31 Dec 2012 reporting period
8.4a Reporting Period From/To/Source/Scope/Explain why the source is excluded 1 Jan 2012/31 Dec 2012/Small sources (leased R&amp;D < 50k SQFT &amp; Commercial/LC < 100k SQFT)/Scope 1 and 2/Pfizer typically does not maintain operational control of the commercial facilities less than 100,000 square feet and research facilities less t
8.5 Reporting Period From/To/Please estimate the uncertainty of the total gross global Scope 1 and 2 emissions figures that you have supplied and specify the sources of uncertainty in your data gathering, handling and calculations/Scope 1 emissions No Response
8.6. Please indicate the verification/assurance status that applies to your Scope 1 emissions Third party verification or assurance underway but not yet complete - last years statement available Proportion of Scope 1 emissions that are verified/assured for 2011 - 2012/01 Jan 2012 - 31 Dec 2012 reporting period
8.6a. Please indicate the proportion of your Scope 1 emissions that are verified/assured More than 0% but less than or equal to 20% More than 90% but less than or equal to 100% More than 90% but less than or equal to 100%
8.6b Reporting Period From/To/Please provide further details of the verification/assurance undertaken, and attach the relevant statements: Type of verification or assurance/Attach the document No Response
2013 Performance Band E B A NA
2013 Score 0 91 100 NA
0. Attachments NA https://www.cdproject.net/sites/2013/83/14683/Investor CDP 2013/Shared Documents/Attachments/InvestorCDP2013/Introduction/Pfizer 2012 Annual Review - full dowload.pdf NA If you have not been presented with a sector module that you consider would be appropriate for your company to answer, please select the module below. If you wish to view the questions first, please see https://www.cdproject.net/en-US/Programmes/Pages/Mor
0. Further Information NA REFERENCES: Pfizer Fact Sheet: http://www.pfizer.com/about/leadership_and_structure/company_fact_sheet.jsp2012 Annual Review: attached and at http://www.pfizer.com/investors/financial_reports/annual_reports/2012/index.jsp NA If you are in these sectors (according to the Global Industry Classification Standard (GICS)), the corresponding sector modules will be marked as default options to your information request. If you want to query your classification, please email respond@c
0.1. Introduction - Please give a general description and introduction to your organization. NA Good health is vital to all of us, and finding sustainable solutions to the most pressing health care challenges of our world cannot wait. That's why we at Pfizer are committed to applying science and our global resources to improve health and well-being NA
0.1. Please give a general description and introduction to your organization. Good health is vital to all of us, and finding sustainable solutions to the most pressing health care challenges of our world cannot wait. That's why we at Pfizer are committed to applying science and our global resources to improve health and well-being
0.2. Please state the start and end date of the year for which you are reporting data. 2012-01-01
SUBSCRIPTION INFO
2014 Performance Band E B A 2014 Performance Band
2014 Score 100 92 1 2014 Score
CDLI leader No No Yes The Climate Disclosure Leadership Index: A Company must: (1)   Make its response public and submit via CDP’s Online Response System (2) Achieve a score within the top 10% of the total regional sample population
Comment NA Comment
CPLI leader No No Yes The Climate Performance Leadership Inde: A company must: (1)Make its response public and submit via CDP’s Online Response System (2) Attain a performance score greater than (3) Disclose gross global Scope 1 and Scope 2 figures (4) Score maximum performanc
Scope 1 emissions 959865 All greenhouse gas (GHG) emissions that are directly from sources that are owned or controlled by the reporting entity.
Scope 2 emissions 705558 All indirect greenhouse gas (GHG) emissions from the consumption of purchased electricity, heat or steam. Indirect GHG emissions are a consequence of the activities of the reporting entity, but occur at sources owned or controlled by another entity.
Target(s) reported abs Absolute/Intensive
Ticker PFE Ticker
Verification/ assurance 12 Audit and verification by a competent and independent organization that uses a standardized set of terms and methods.
SUBSCRIPTION INFO
2.1. Are you able to identify which of your operations are located in water-stressed regions? No Response 4 answers 4 answers NA
0.4. Exclusions Are there any geographies, activities, facilities or types of water inputs/outputs within this boundary which are not included in your disclosure? NA Yes NA NA
2.2b. You may explain here why you are not able to identify which of your operations are located in regions subject to water stress or water-related risk and whether you have plans to explore this issue in the future No Response 3 answers 3 answers NA
0.4aList of Exclusions & Reason for Exclusions-Transparency & Reporting No Response Answered Answered NA
1.1. Does your company have a water policy, strategy or management plan? No Yes Yes NA
2.1bPlease list the water-stressed regions where you have operations and the percentage of your total operations in that area NA Singapore/Total country located in water stress area to total operations./1 – 10China/Total country located in water stress area to total operations./1 – 10Brazil/Total country located in water stress area to total operations./1 – 10Venezuela/Total countr NA NA
2.1bPlease list the water-stressed regions where you have operations and the percentage of your total operations in that area-Transparency & Reporting No Response 4 answers 4 answers NA
2.2. Do you use other indicators (besides water stress) to identify operations which are located in regions subject to water-related risk? NA NA NA NA
0.1. Introduction Please give a general description and introduction to your organization. NA Pfizer Inc: "Working Together for a Healthier World" Good health is vital to all of us, and finding sustainable solutions to the most pressing health care challenges of our world cannot wait. NA NA
0.2. Reporng Year Please state the start and end date of the year for which you are reporting data. 2.0. Enter the period that will be disclosed. NA 01-01-2011 - 31-12-2011 NA NA
0.3. Reporting Boundary Please indicate the category that describes the company, entities, or group for which you are reporting. NA Companies, entities or groups over which operational control is exercised. NA NA
2.3. Please specify the total percentage of your operations that are located in the regions at risk which you identified in questions 2.1 and/or 2.2 NA Yes NA NA
2.4. Please specify the basis you use to calculate the percentages used for questions 2.1 and/or 2.2 NA Other NA NA
1.1a. Please describe your policy, strategy or plan, including the highest level of responsibility for it within your company and its geographical reach-Transaprency & Reporting Australia/CCA's Water Policy covers all aspects of water related operations activities from both municipal and groundwater sources across the beverage and food businesses. Global/Water Strategy: Pfizer has a global Water Sustainability Program that was established in 2010 and is modelled after the UNGC Water Mandate. The strategy is based on the six core elements of the mandate framework, each of which is outlined below. F United States of America/We have a philosophy to limit water waste and a strategy to identify reduction opportunities from development through operations through supply chain. We build our stores to green building standards (LEED and Green Globes), and e NA
1.1b. Does the policy, strategy or plan specify water reduction, quality or efficiency targets or other water-related goals? NA Global NA NA
1.1bDoes the water policy, strategy or plan specify water-related targets or goals? No Yes Yes NA
0.4aList of Exclusions & Reason for Exclusions NA Our materiality assessment is based on the WRI GHG Protocol guidance of a 5% materiality threshold. Currently, the 5% represents the remaining water use data which is estimated for small sources which are leased: (1) R&D < 50k SQFT (2) Commercial < 100k S NA NA
SUBSCRIPTION INFO
0.2. Reporting Year 2012-01-01
0.3. Reporting Boundary Companies, entities or groups over which operational control is exercised
0.4. Are there any geographies, activities, facilities or types of water inputs/outputs within this boundary which are not included in your disclosure? Yes
0.4a. List of Exclusions & Reason for Exclusions-Transparency & Reporting 2 answers
0.4a. List of Exclusions & Reason for Exclusions-Transparency & Reporting (value) #NAME?
1.1. Does your company have a water policy, strategy or management plan? No Yes Yes
1.1a. Please describe your policy, strategy or plan, including the highest level of responsibility for it within your company and its geographical reach-Transaprency & Reporting Australia/CCA's Water Policy covers all aspects of water related operations activities from both municipal and groundwater sources across the beverage and food businesses. NA United States of America/We have a philosophy to limit water waste and a strategy to identify reduction opportunities from development through operations through supply chain. We build our stores to green building standards (LEED and Green Globes), and e
1.1a. Please describe your policy, strategy or plan, including the highest level of responsibility for it within your company and its geographical reach-Transaprency & Reporting (value) NA
1.1b. Does the water policy, strategy or plan specify water-related targets or goals? Yes
1.1c. Description of Target/goal, its type and geographical reach -Transparency & Reporting 2 answers
1.1c. Description of Target/goal, its type and geographical reach -Transparency & Reporting (value) #NAME?
1.1d. You may explain here why your company does not have a water policy, strategy or plan and if you intend to put one in place. NA
1.2. What specific actions has your company taken to manage water resources or engage stakeholders in water-related issues and what are their outcomes?-Transparency & Reporting 2 answers
1.2. What specific actions has your company taken to manage water resources or engage stakeholders in water-related issues and what are their outcomes?-Transparency & Reporting (value) #NAME?
2.1. Are any of your operations located in water-stressed regions? Yes
2.1a. Please specify the method(s) you use to characterize water-stressed regions- Environmental policy & Reporting WBCSD
2.1a. Please specify the method(s) you use to characterize water-stressed regions- Environmental policy & Reporting (value) #NAME?
2.1b. Please list the water-stressed regions where you have operations and the percentage of your total operations in that area-Transparency & Reporting 2 answers
2.1b. Please list the water-stressed regions where you have operations and the percentage of your total operations in that area-Transparency & Reporting (value) #NAME?
2.2. Are there other indicators (besides water stress) which you wish to report that help you to identify which of your operations are located in regions subject to water-related risk? Yes
2.2a. Please list the relevant risk indicator of your total operations in that area-Environment Policy and Reporting #NAME?
2.2b. You may explain here why you do not wish to report or why you do not use other indicators to identify which of your operations are located in regions subject to water-related risk. NA
2.3. Please specify the total proportion of your operations that are located in the regions at risk which you identified in questions 2.1 and/or 2.2. 0 3.8 99
2.4. The basis to use to calculate the percentages used for questions 2.1 and/or 2.2 2 answers
2.4. The basis to use to calculate the percentages used for questions 2.1 and/or 2.3 (value) #NAME?
2.5. Do any of your key inputs or raw materials (excluding water) come from regions subject to water-related risk? Yes
2.5a. Please state or estimate the percentage of your key water-intensive inputs (excluding water) that come from these regions-Transparency & Reporting #NAME?
2.5b. You may explain here why you are not able to identify if any of your key inputs or raw materials come from regions subject to water-related risk and whether you have plans to explore this issue in the future. NA
3.1. Is your company exposed to water-related risks (current or future) that have the potential to generate a substantive change in your business operation, revenue or expenditure? Yes
3.1a. Please describe the current and/or future risks to your operations, the ways in which these risks affect or could affect your operations and your current or proposed strategies for managing them-Transparency & Reporting NA
3.1a. Please describe the current and/or future risks to your operations, the ways in which these risks affect or could affect your operations and your current or proposed strategies for managing them-Transparency & Reporting (value) #NAME?
3.1b. Please explain why you do not consider your company to be exposed to any water-related risks that have the potential to generate a substantive change in your business operation, revenue or expenditure. NA
3.1c. Please explain why you do not know if your company is exposed to any water-related risks that have the potential to generate a substantive change in your business operation, revenue or expenditure, and your plans to assess this risk in the future. NA
3.2. Country or geographical scale-Environment Policy & Reporting Other:
3.2. What methodology do you use to analyze water-related risk across your operations?-Transparency & Reporting Answered
3.2. What methodology do you use to analyze water-related risk across your operations? General risk management is described in 3.1b. Water-related risks are assessed as part of the general risk management. At asset level, Philips continues to monitor its exposure to water-related risks and is working at individual plant level to reduce and
3.3. Do you require your key suppliers to report on their water use, risks and management? Yes
3.4. Is your supply chain exposed to water-related risks (current or future) that have the potential to generate a substantive change in your business operation, revenue or expenditure? Yes
3.4b. Please explain why you do not consider your supply chain to be exposed to any water-related risks that have the potential to generate a substantive change in your business operation, revenue or expenditure. NA
3.4c. Please explain why you do not know if your supply chain is exposed to water-related risks that have the potential to generate a substantive change in your business operation, revenue or expenditure, and your plans to assess this risk in the future. NA
4.1. Has your business experienced any detrimental impacts related to water in the past five years? Yes
4.1. Please describe any detrimental impacts to business related to water your company has faced in the past five years, their financial impacts and whether they have resulted in any changes to company practices- Transparency & Reporting Answered
5.1. Do water-related issues present opportunities (current or future) that have the potential to generate a substantive change in your business operation, revenue or expenditure? Yes
5.1a. Please describe the current and/or future opportunities, the ways in which these opportunities affect or could affect your operations and your current or proposed strategies for exploiting them-Environmental Policy & Reporting 3 answers
5.1a. Please describe the current and/or future opportunities, the ways in which these opportunities affect or could affect your operations and your current or proposed strategies for exploiting them-Environmental Policy & Reporting (value) #NAME?
5.1b. Please explain why you do not consider water-related issues to present opportunities to your company that have the potential to generate a substantive change in your business operation, revenue or expenditure or supply chain. NA
5.1c. Please explain why you do not know whether water-related issues present opportunities to your company that have the potential to generate a substantive change in your business operation, revenue or expenditure. NA
6.1. Has your company identified any linkages or trade-offs between water and carbon emissions in its operations or supply chain? Yes
6.1a. Please describe the linkages or trade-offs between water and carbon emissions in its operations or supply chain?--Transparency & Reporting 2 answers
6.1a. Please describe the linkages or trade-offs and the related management policy or action between water and carbon emissions in its operations or supply chain?-Transparency & Reporting (value) #NAME?
7.1. Are you able to provide data, whether measured or estimated, on water withdrawals within your operations? Yes
7.1a. Please report the water withdrawals within your operations for the reporting year-Transparency & Reporting 0
7.1a. Please report the water withdrawals within your operations for the reporting year-Transparency & Reporting (value) 0
7.1b. Please explain why you are not able to provide data for water withdrawals. NA
7.2. Are you able to provide data, whether measured or estimated, on water recycling/reuse within your operations? Yes
7.2a. Please report the water recycling/reuse within your operations for the reporting year-Transparency & Reporting 3 answers
7.2a. Please report the water recycling/reuse within your operations for the reporting year-Transparency & Reporting (value) #NAME?
7.2b. Please explain why you are not able to provide data for water recycling/reuse within your operations. NA
7.2b. Please explain why you are not able to provide data for water recycling/reuse within your operations-Transparency & Reporting No Response
7.3. Please use this space to describe the methodologies used for questions 7.1 and 7.2 or to report withdrawals or recycling/reuse in a different format to that set out above. Background:With the additional metrics collected using key GRI indicators for water, Pfizer was better positioned to report our 2012 water footprint more comprehensively and accurately: EN8: Total water withdrawal by sourceEN9: Water sources significant
7.3. Please use this space to describe the methodologies used for questions 7.1 and 7.2 or to report withdrawals or recycling/reuse in a different format to that set out above-Transparency & Reporting Answered
7.4. Are any water sources significantly affected by your company's withdrawal of water? No
7.4a. Please list any water sources significantly affected by your company's withdrawal of water. NA
7.4b. You may explain here why your company's withrawal of water does not significantly affect any water sources. Most of Pfizer’s water withdrawals are subject to a regulatory framework. Generally, water use is regulated by a local governing body that is responsible for ensuring water use does not adversely impact the availability of water sources. In 2012, as par
7.4b. You may explain here why your company's withrawal of water does not significantly affect any water sources-Transparency & reporting Answered
7.4c. Please explain why you do not know if any water sources are significantly affected by your company's withdrawal of water. NA
8.1. Are you able to identify discharges of water from your operations by destination, by treatment method and by quantity and quality using standard effluent parameters? Yes
8.1a. Please explain why you are not able to identify discharges from your operations by destination, treatment method , quantity and quality, and whether you have any plans to put in place systems that would enable you to do so. NA NA
8.2. Did your company pay any penalties or fines for significant breaches of discharge agreements or regulations in the reporting period? No NA
8.2a. Please describe the quality, quantity and destination of the water that was the subject of the significant breach(es), the associated fines and any actions taken to minimise the risk of future non-compliance NA NA
8.3. Are any water bodies and related habitats significantly affected by discharges of water or runoff from your operations? Yes NA
8.3a. Please list any water bodies and related habitats which are significantly affected by discharge of water or runoff from your operations #NAME? NA
8.3b. You may explain here why your company's discharge of water does not significantly affect any water bodies or associated habitats. NA NA
8.3b. You may explain here why your company's discharge of water does not significantly affect any water bodies or related habitats-Tansparency & Reporting No Response NA
8.3c. Please explain why you do not know if any water bodies and associated habitats are significantly affected by discharge of water or runoff from your operations. NA NA
9.1. Please provide any available financial intensity values for your company's water use across its operations 3 answers NA
9.1. Please provide any available financial intensity values for your company's water use across its operations (value) #NAME? NA
9.2. Please provide any available water intensity values for your company's products or services across its operations. #NAME? NA
Please enter the name of the individual that has signed off (approved) the response and their job title Mr. Stephen Brooks Pfizer - Global VP, Environment, Health &amp; Safety July 9, 2013 NA
CECP (Committee Encouraging Corporate Philanthropy)
SUBSCRIPTION INFO
SUBSCRIPTION INFO
2014 CEI Rating 100 NA
Firm-wide Organizational Competency Programs (10 points) Yes Yes NA
Fortune 1000 850 40 1 NA
Has Employer-Supported Employee Resource Group OR Firm-Wide Diversity Council (10 points) Yes Yes NA
Has Parity Across Other “Soft” Benefits for Partners (10 points) Yes Yes NA
Headquarters Location New York, NY NA
Offers Partner Health/Medical Insurance (15 points) Yes Yes NA
Offers Transgender-Inclusive Health Insurance Coverage (10 points) Yes Yes NA
Positively Engages the External LGBT Community (15 points) Yes Yes NA
Prohibits Discrimination Based on Gender Identity or Expression (15 points) Yes Yes NA
Prohibits Discrimination Based on Sexual Orientation (15 points) Yes Yes NA
Responsible Citizenship Employers will have 25 points deducted from their score for a large-scale official or public anti-LGBT blemish on their recent records (-25 points) NA Yes NA
SUBSCRIPTION INFO
Reduce 0 52 52 NA
Report 0 11 12 NA
Review 0 16 27 NA
SUBSCRIPTION INFO
Rank by Context-Based Score (1 to 100) 100 70 1 Climate counts rank
Sustainable N N Y If a company has a score of less than or equal to one (?1), it is considered “sustainable”, whereas a company with a score greater than one (>1) is considered “unsustainable”
SUBSCRIPTION INFO
SUBSCRIPTION INFO
Disclosure (Percent of Max 23 points) 0 83 100 NA
Grand Total (Percent of Max 69 points) 0 77 100 NA
Policies (Percent of Max 18 points) 0 83 100 NA
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
Reported Scope 3 Total (tCO2e) 670000000 - 0 Indicated the total reported Scope 3 (all other indirect emissions) of the company in metric tonnes of CO2 equivalent (tCO2e) as defined by the Greenhouse Gas Protocol. Where no Scope 3 emissions are reported, this is recorded as "No Data"
Scope 1+2 Intensity 11162.43 39.45 0.3 Intensity is calculated by adding together a company's Scope 1 and Scope 2 emissions and dividing by its turnover.
Global 800 Carbon Rank 800 189 1 Carbon Ranking of 800 international companies. Ranking is determined by EIO Methodology. See Source Info sheet for comments on it
No. of Scope 3 Categories Reported 1 - 15 This column indicates the number of Scope 3 Categories reported. Once placed into one of the four Disclosure Categories, companies are ranked by the number of Scope 3 categories disclosed.
Reported Scope 1+2 Total (tCO2e) 282000000 2660000 843 The total reported Scope 1 (all direct emissions) and Scope 2 (indirect electricity emissions) of the company in metric tonnes of CO2 equivalent (tCO2e) as defined by the Greenhouse Gas Protocol
Accepted or Inferred Scope 3 Intensity 8547.13 291.54 64.51 Unless the company reports all 15 Scope 3 categories as defined by the Greenhouse Gas Protocol Corporate Value Chain (Scope 3) Standard, an inferred figure based on the highest reported intensity for that sector, across the Global ET Universe, is shown
Category No Public Data Yellow Public, Complete, and Verified data Companies are placed into one of four data or 'disclosure' categories: 1) Public, Complete, and Verified data; 2) Public, Complete, and Unverified data; 3) Public, Incomplete, Verified or Unverified data; 4) No Public Data
Combined Scope 1+2+3 Intensity 12161.68 185.22 34.24 Combined Scope 1+2_3 Intensity is calculated by adding together a company's Scope 1 and Scope 2 emissions at 100% (disclosed or inferred) + 50% of Scope 3 emissions (disclosed or inferred).
Market Value ($Million) 1667.87 184648 358143.1 A company's market value, or market capitalism (number of shares times x share price). This value was taken on 23.08.2011
SUBSCRIPTION INFO
Sum of Biogenic CO2 emissions 2.9 NA 23623772.5 Total biogenic CO2 emissions.
Sum of CO2 emissions (non-biogenic) 0.3 526408.4 53858607.2 Total non-biogenic CO2 emissions
Sum of Gases with No Listed GWP (metric tons) 0.3397 NA 1036.4
Sum of HFC emissions 2558.79 NA 19215.8
Sum of HFE emissions NA NA
Sum of Methane (CH4) emissions 0.21 412.65 2491216.14 Total methane emissions
Sum of NF3 emissions 5332 NA 21231.68
Sum of Nitrous Oxide (N2O) emissions 0.31 1047.8 10675387.54
Sum of PFC emissions 33930.1 NA 1221318.27
Sum of SF6 emissions 4254.2 NA 153581.4
Total reported direct emissions 30.03 527868.85 54200390.452 Total emissions of CO2 and other gases in metric tons.
Industry Description NA NA Description of the type of industry the facility serves.
Is Some CO2 captured on-site and therefore not emitted? N NA Y Indicates if all CO2 is emitted or if some is sequestered.
Number of reporting facilities 1 1 50 Number of facilities reported to the EPA.
Percentage of facilities that emit pollutants 2 100 100 Percent of reporting facilities that emit pollutants other than CO2.
Percentage of facilities that employ continuous emissions monitoring 6 NA 100
SUBSCRIPTION INFO
ceo:numberOfRatings 1 259 4026 The number of ratings of the CEO
ceo:pctApprove 0 58 100 Percent of ratings of the CEO that were approving
ceo:title NA The title of the company's CEO
employer:numberOfRatings 1 844 6549 The number of Glassdoor users who have rated this company as a place to work.
Glassdoor Employer Ratings 1 3.2 5 The Top Companies for Work-Life Balance list is based on employee feedback shared in company reviews on Glassdoor.
SUBSCRIPTION INFO
Executive Diversity 0 0.11 0.41 Percentage of officers and directors that are female.
Percentage of Profit 0 0.013 1.086 Percentage of profit donated.
Rank 500 140 1 NA
Toxicity produced 773771631 1928993 0 In pounds.
Toxicity released 113515588 225006 0 In pounds.
SUBSCRIPTION INFO
Guidelines NA GRI - G3 NA This field indicates which version of the GRI Guidelines is used for the reporting. As of publication year 2009, GRI only includes reporting that makes use of the G3 Guidelines, which were released in October 2006.
Integrated No No Yes GRI currently has two classifications for defining organization size: 'SME' and 'Large'. SME stands for Small- and Medium-sized Enterprises. GRI follows the definition for SMEs as set by the European Union: SMEs have 250 employees or less and have a yearl
Publication Year 2013 GRI currently has two classifications for defining organization size: 'SME' and 'Large'. SME stands for Small- and Medium-sized Enterprises. GRI follows the definition for SMEs as set by the European Union: SMEs have 250 employees or less and have a yearl
Region NA Northern America NA Region the organization operates in.
Report Html Address NA http://www.pfizer.com/responsibility/corporate_responsibility_report NA URL of the report location.
Report Pdf Address NA http://www.pfizer.com/files/investors/financial_reports/annual_reports/2012/downloads/pfizer_12ar_entire_site.pdf NA Location of a PDF version of the report.
Report Title NA 2012 Pfizer Corporate Responsibility Report NA Title of the report.
Sector NA Healthcare Products NA Industry sector.
Sector Supplements (Final) NA Not Used NA This field indicates if the reporting organization has made use of one of the final Sector Supplements and which one. If ‘not used’ is indicated, it means that one of the final Sector Supplements is applicable, but has not been used. If ‘not applicable’ i
Size NA MNE NA GRI currently has two classifications for defining organization size: 'SME' and 'Large'. SME stands for Small- and Medium-sized Enterprises. GRI follows the definition for SMEs as set by the European Union: SMEs have 250 employees or less and have a yearl
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
Industry Pharmaceuticals The company's industry sector
Public Note NA Comments on any public note about the statement
Sector Healthcare The company's industry sector
Statement http://www.pfizer.com/files/responsibility/workplace_responsibility/pfizer_cali_transparency_act.pdf The company's statement location
Statement--Trasparency No Yes Yes Companies with a posted statement addressing at least three of the five SB-657 requirements are awarded a check mark.
Website http://www.pfizer.com The company's web site
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
Disclosure 0 62.4 100 Environmental disclosure was included as a stand-alone score to assess each company’s transparency with regard to its environmental performance. Specifically, this score evaluates the breadth and quality of company environmen
Green Score 21.4 68.7 82.9 NA
Envtl. Mgmt. 21.3 76.6 91.9 Based on an analysis of companies tracked in Sustainalytics’ Global Platform, the Environmental Management Score is an assessment of how a company manages its environmental performance through policies, programs, targets, certifications, and the like. To
Envtl. Impact 0 62.3 89 Based on data compiled by Trucost, this is a comprehensive, quantitative, and standardized measurement of the overall environmental impact of a company’s global operations. More than 700 metrics—including emissions of nine key greenhouse gases, water use,
SUBSCRIPTION INFO
Carbon Productivity 0.003 0.34 0.97 GHG Productivity defined as Revenue ($US) / Total Greenhouse gas (GHG) Emissions (CO2e).
Energy Productivity 0.021 0.401 0.971 Energy Productivity defined as Revenue ($US) / Total Energy Consumption (GJ).
Newsweek Green Score 0.014 0.41 0.851 This score is derived from the following component scores: an Energy Productivity,Carbon Productivity, Water Productivity, Waste Productivity, Reputation, Pay Link, Sustainability Themed Committee, Audit ; weighted at 45 percent, 45 percent, and 10 percen
Pay Link No Yes Yes A mechanism to link the remuneration of any member of a company's senior executive team with the achievement of environmental performance targets.
Rank 500 144 1
Reputation 0.005 0.099 1.0 The Reputation score is made up of two components: (1) The RepRisk Index, which is a quantitative measure that captures criticism and quantifies a company exposure to ESG risks. (2) The second component is based on the number of environmental issues that
Sustainability Themed Committee No Yes Yes The existence of a committee at the Board of Directors level whose mandate is related to the sustainability of the company, including but not limited to environmental matters.
Waste Productivity 0.014 0.247 0.97 Waste Productivity is defined as Revenue ($US) / [Total waste generated (metric tonnes) – waste recycled/reused (metric tonnes)].
Water Productivity 0.028 0.281 0.992 Water Productivity is defined as Revenue ($US) / Total water use (m3).
SUBSCRIPTION INFO
Envtl. Mgmt. 28.6 76.6 91.9 Based on an analysis of companies tracked in Sustainalytics’ Global Platform, the Environmental Management Score is an assessment of how a company manages its environmental performance through policies, programs, targets, certifications, and the like. To
Green Score 0 68.7 100 NA
Rank 500 91 1 NA
Disclosure 0 62.4 100 Environmental disclosure was included as a stand-alone score to assess each company’s transparency with regard to its environmental performance. Specifically, this score evaluates the breadth and quality of company environmen
SUBSCRIPTION INFO
Carbon Productivity 0.015 0.34 0.963 GHG Productivity defined as Revenue ($US) / Total Greenhouse gas (GHG) Emissions (CO2e).
Energy Productivity 0.007 0.401 0.957 Energy Productivity defined as Revenue ($US) / Total Energy Consumption (GJ).
Newsweek Green Score 0.0 0.41 0.843 This score is derived from the following component scores: an Energy Productivity,Carbon Productivity, Water Productivity, Waste Productivity, Reputation, Pay Link, Sustainability Themed Committee, Audit ; weighted at 45 percent, 45 percent, and 10 percen
Pay Link No Yes Yes A mechanism to link the remuneration of any member of a company's senior executive team with the achievement of environmental performance targets.
Rank 500 222 1
Reputation 0.005 0.099 1 The Reputation score is made up of two components: (1) The RepRisk Index, which is a quantitative measure that captures criticism and quantifies a company exposure to ESG risks. (2) The second component is based on the number of environmental issues that
Sustainability Themed Committee No Yes Yes The existence of a committee at the Board of Directors level whose mandate is related to the sustainability of the company, including but not limited to environmental matters.
Waste Productivity 0.014 0.247 0.97 Waste Productivity is defined as Revenue ($US) / [Total waste generated (metric tonnes) – waste recycled/reused (metric tonnes)].
Water Productivity 0.012 0.281 0.992 Water Productivity is defined as Revenue ($US) / Total water use (m3).
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
Corporate Governance 3 0 0 The scores for each ESG scope issue ranges from 0-3. The scoring refers to the number of times the company was criticized in relation to that scope issue: 0 = little or no exposure in the past 4 years; 1 = 5 direct relations in the past 4 years; 2 = 10 direct relations in the past 4 years; 3 = 20 direct relations in the past 4 years.
Current RRI 86 0 0 The RepRisk Index (RRI) is a quantitative risk measure that captures criticism and quantifies a company's exposure to controversial environmental, social and governance (ESG) issues. It does not measure a company's overall reputation, but rather is an indicator of their reputational risk.The Current RRI value indicates the current level of criticism about a company.
Employee Relations 3 0 0 The scores for each ESG scope issue ranges from 0-3. The scoring refers to the number of times the company was criticized in relation to that scope issue: 0 = little or no exposure in the past 4 years; 1 = 5 direct relations in the past 4 years; 2 = 10 direct relations in the past 4 years; 3 = 20 direct relations in the past 4 years.
Environmental FootPrint 3 0 0 The scores for each ESG scope issue ranges from 0-3. The scoring refers to the number of times the company was criticized in relation to that scope issue: 0 = little or no exposure in the past 4 years; 1 = 5 direct relations in the past 4 years; 2 = 10 direct relations in the past 4 years; 3 = 20 direct relations in the past 4 years.
SUBSCRIPTION INFO
Rank 400 328 1 REPORTWATCH RATING
Report Rating D B A REPORTWATCH RATING
SUBSCRIPTION INFO
SUBSCRIPTION INFO
Value of USG Contracts (in millions) 990 912 1 Value of Iranian contracts.
Withdrawn NA Was the association with Iran withdrawn?
Nationality USA Country the company is in.
On the list Yes Yes Is the company on the list.
SUBSCRIPTION INFO
SUBSCRIPTION INFO
include_measurement 0 1 1 Does your COP identify targets, define performance indicators and measure outcomes?
references_anti_corruption 0 1 1 Does your COP contain description of actions, and when relevant policies, related to anti-corruption?
references_environment 0 1 1 Does your COP contain description of actions, and when relevant policies, related to the environment?
references_human_rights 0 1 1 Does your COP contain description of actions, and when relevant policies, related to human rights?
references_labour 0 1 1 Does your COP contain description of actions, and when relevant policies, related to labour rights?
starts_on NA 07/01/2012 NA Start Date
differentiation NA active NA At what level is the declarer?
ends_on NA 12/01/2013 NA End Date
format NA annual_report NA How is your COP shared with stakeholders?
SUBSCRIPTION INFO
IT Rank 30 NA 1 The most attractive employers in the IT field.
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
Weighted score 1.2 4.1 5.9

Flags

(Other Indicators - things that don’t affect ratings but that help identify or classify companies)

SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
SUBSCRIPTION INFO
You have put report(s) in your cart
Go to my cart
Ok